Fenwick & West has advised Attovia Therapeutics. Cooley LLP has advised the underwriters. Attovia Therapeutics, a clinical-stage biopharmaceutical company, has announced the pricing of its upsized...
Attovia Therapeutics Launches Upsized $289 Million Initial Public Offering
Scribe Therapeutics Completes $155.51 Million Initial Public Offering and Private Placement
Fenwick has advised Scribe Therapeutics. Latham & Watkins has advised the underwriters. Scribe Therapeutics Inc., a clinical-stage biotechnology company specializing in in vivo CRISPR technologies, has...
Remix Therapeutics and Passage Bio Announce Merger and $100 Million Private Placement
Latham & Watkins LLP has advised Remix Therapeutics. Fenwick & West LLP has advised Passage Bio. Cooley LLP has advised Goldman Sachs & Co. LLC, Jefferies...
Merger Agreement Between Treeline Biosciences and Standard BioTools
Freshfields LLP and Richards, Layton & Finger, P.A. have advised Standard BioTools. Fenwick & West LLP has represented Treeline Biosciences. Treeline Biosciences and Standard BioTools Inc....
BitGo Raises $212 Million in Initial Public Offering on NYSE
Fenwick & West has advised BitGo. BitGo, a digital asset infrastructure company, has completed its initial public offering, raising approximately $212 million. The offering consisted of...
Belite Bio Prices $350 Million Public Offering of American Depositary Shares
O’Melveny & Myers LLP and Maples and Calder (Hong Kong) LLP have advised Belite Bio. Wilson Sonsini Goodrich & Rosati has advised Belite Bio on patent...
MNTN’s $187 Million IPO
Latham & Watkins represented MNTN, Inc. in the offering, and Fenwick & West represented the underwriters. MNTN, Inc. (NYSE: MNTN) announced its initial public offering. The...
ACELYRIN’s Merger with Alumis
Fenwick & West and Paul Hastings advised ACELYRIN, INC. on the transaction, and Cooley advised Alumis Inc. ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company...
Maze Therapeutics’ $140 Million Upsized Initial Public Offering
Fenwick & West represented Maze Therapeutics in the offering, and Davis Polk & Wardwell represented the underwriters. Maze Therapeutics, Inc. (Nasdaq: MAZE) announced its upsized initial...
Gritstone bio’s $32.5 Million Common Stock Offering
Fenwick & West and Goodwin Procter represented Gritstone bio, Inc. in the offering, and Cooley represented the underwriters. Gritstone bio, Inc. (Nasdaq: GRTS) announced the pricing of...
JN BIDCO’s Acquisition of Impel Pharmaceuticals
Fenwick & West and Sidley Austin are representing Impel Pharmaceuticals Inc. in the transaction. JN BIDCO LLC announced the acquisition of Impel Pharmaceuticals Inc. (OTCQX: IMPL)....
Novartis AG’s Acquisition of Chinook Therapeutics
Fenwick & West LLP represented Chinook Therapeutics, Inc. on the transaction, while Hogan Lovells US LLP represented Novartis AG. Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company, announced...